COMPARATIVE ANALYSIS OF STAGING MODALITIES IN CARCINOMA STOMACH: UNRAVELING THE SYNERGY BETWEEN STAGING LAPAROSCOPY AND CECT ABDOMEN

ABHINAV CHAUDHARY; MANISH YADAV; ARVIND KANWAR; PARIKSHIT MALHOTRA; UK CHANDEL

doi:10.22159/ijcpr.2024v16i2.4047

Authors

ABHINAV CHAUDHARY Department of Surgery, Dr RPGMC, Tanda, Himachal Pradesh, India
MANISH YADAV Department of Surgery, Dr YSPGMC Nahan, Himachal Pradesh, India
ARVIND KANWAR Department of Surgery, Dr YSPGMC Nahan, Himachal Pradesh, India https://orcid.org/0009-0003-9070-5206
PARIKSHIT MALHOTRA Department of Surgery, SLBSGMC Nerchowk, Himachal Pradesh, India
UK CHANDEL Department of Surgery, SLBSGMC Nerchowk, Himachal Pradesh, India

DOI:

https://doi.org/10.22159/ijcpr.2024v16i2.4047

Keywords:

Stomach carcinoma, Staging laparoscopy, Contrast-enhanced computed tomography, Diagnostic modalities, Personalized treatment, Gastric cancer management

Abstract

Objective: Stomach carcinoma, a complex challenge in oncology, necessitates refined staging for optimal therapeutic strategies. The comparative analysis of staging laparoscopy and contrast-enhanced computed tomography (CECT) emerges as a key exploration in this context.

Methods: Conducted at Indira Gandhi Medical College and Hospital, Shimla, this prospective study spanned one year. Biopsy-proven gastric carcinoma patients meeting inclusion criteria underwent extensive investigations, including CECT, staging laparoscopy, and diagnostic lavage. The study employed specific protocols for each procedure, ensuring comprehensive data collection.

Results: Analysis of 32 cases revealed a prevalence in the 61-70 y age group, predominantly affecting males. Diverse symptoms included pain (68.75%) and palpable mass (81.2%). Well-differentiated adenocarcinoma (43.8%) dominated, with distinct age-related patterns. The study showcased the intricate nature of gastric carcinoma, demanding tailored diagnostic approaches.

Conclusion: This study unravels the interplay between staging laparoscopy and CECT in gastric carcinoma, offering a comprehensive staging approach. The nuanced insights gained through their synergy address individual limitations, contributing to more precise evaluations and tailored interventions. The collaborative use of these modalities promises to enhance precision, ultimately improving patient outcomes in gastric carcinoma management.

Downloads

Download data is not yet available.

References

Ajani JA, D’Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P. Gastric cancer version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(10):1286-312.

Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines. 5th ed. Gastric Cancer. 2018;24(1):1-21.

Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D, ESMO Guidelines Committee. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27Suppl 5:v50-7. doi: 10.1093/annonc/mdw329, PMID 27664261.

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20. doi: 10.1056/NEJMoa055531, PMID 16822992.

Washington K. 7th edition of the AJCC cancer staging manual: stomach. 7th ed. Annals of Surgical Oncology. 2010;17(12):3077-9. doi: 10.1245/s10434-010-1362-z, PMID 20882416.

Japanese Gastric Cancer Association. English edition. Japanese classification of gastric carcinoma. Gastric Cancer. 2011;14(2):101-12.

Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715-21. doi: 10.1200/JCO.2010.33.0597, PMID 21444866.

Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27Suppl 5:v38-49. doi: 10.1093/annonc/mdw350, PMID 27664260.

Hasegawa T, Kubo N, Ohira M, Sakurai K, Toyokawa T, Yamashita Y. Impact of body mass index on surgical outcomes after esophagectomy for patients with esophageal squamous cell carcinoma. J Gastrointest Surg. 2015;19(2):226-33. doi: 10.1007/s11605-014-2686-y, PMID 25398407.

Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol European Journal of Surgical Oncology. 2014;40(1):12-26. doi: 10.1016/j.ejso.2013.10.019, PMID 24290371.

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4. doi: 10.1245/s10434-010-0985-4, PMID 20180029.

Beom SH, Choi YY, Baek SE, Li SX, Lim JS, Son T. Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. BMC Cancer. 2018;18(1):1116. doi: 10.1186/s12885-018-4998-x, PMID 30442107.

Li Z, Shan F, Wang Y. Laparoscopic D2 lymphadenectomy plus complete mesogastrium excision (D2+CME) for gastric cancer: a single-center, high-volume experience. Ann Surg Oncol. 2021;28(1):399-407. doi: 10.1245/s10434-020-08731-y.

Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol. 2017;3(9):1237-44. doi: 10.1001/jamaoncol.2017.0515, PMID 28448662.

Mezhir JJ, Shah MA, Jacks LM, Brennan MF, Coit DG, Strong VE. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol. 2010;17(12):3173-80. doi: 10.1245/s10434-010-1183-0, PMID 20585870.

Ahn HS, Lee HJ, Hahn S, Kim WH, Lee KU, Sano T. Evaluation of the seventh American Joint Committee on Cancer/International Union Against Cancer Classification of gastric adenocarcinoma in comparison with the sixth classification. Cancer. 2010;116(24):5592-8. doi: 10.1002/cncr.25550, PMID 20737569.